CLAIMS

1. A compound having the structure (I):



(I)

and pharmaceutically acceptable derivatives thereof;

wherein n is an integer from 0-4;

R_1 is hydrogen, $-NH_2$, -NHMe, -NHAc, -OH, F, -OMe, -CN, or -NH(C=O)OEt;

R_2 is hydrogen, $-NR_AR_B$, $-OR_A$, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_A and R_B are each independently hydrogen or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

each occurrence of R_3 is independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group $-G-R_C$, wherein G is absent or is $-CH_2-$, $-NR_D-$, -O-, or (C=O), and wherein R_C is hydrogen, $-NR_FR_G$, $-OR_F$, $-SR_F$, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_D, R_F and R_G are each independently hydrogen, $-NR_xR_y$, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_D and R_C or R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R_x and R_y is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_x and R_y taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

2. The compound of claim 1, wherein the compound has the structure:



wherein R_{3a} and R_{3b} are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group –G-R_C, wherein G is absent, $-CH_2-$,
$-NR_D-$, -O-, or (C=O), and wherein R_C is hydrogen, $-NR_FR_G$, $-OR_F$, $-SR_F$, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_D, R_F and R_G are each independently hydrogen, $-NR_xR_y$, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_D and R_C or R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R_x and R_y is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_x and R_y taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

3. The compound of claim 1, wherein the compound has the structure:



wherein R_{3a} and R_{3b} are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group $-G-R_C$, wherein G is absent, $-CH_2-$, $-NR_D-$, -O-, or (C=O), and wherein R_C is hydrogen, $-NR_FR_G$, $-OR_F$, $-SR_F$, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_D, R_F and R_G are each independently hydrogen, $-NR_xR_y$, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_D and R_C or R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R_x and R_y is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_x and R_y taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

4. The compound of claim 1, wherein the compound has the structure:



;

wherein R_1, R_2, R_F and R_G are as defined in claim 1.

5. The compound of claim 1, wherein the compound has the structure:



;

wherein R_1, R_2, R_F and R_G are as defined in claim 1.

6. The compound of claim 1, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 1.

7. The compound of claim 1, wherein the compound has the structure:



wherein q and r are each independently 0 or 1; and R_1, R_2, R_F and R_G are as defined in claim 1.

8. The compound of claim 1, wherein the compound has the structure:



wherein q and r are each independently 0 or 1; and R_1, R_2, R_F and R_G are as defined in claim 1.

9. The compound of claim 1, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 1.

10. The compound of claim 1, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 1.

11. The compound of claim 1, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 1;

m is 0, 1 or 2; and

R_F is an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

12. The compound of claim 1, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 1; and

R_F is hydrogen, a protective group or an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

13. The compound of claim 1, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 1;

G is CH_2 or –(C=O); and

X is O, S, C=O, S=O, $C=CR_4R_5$, NR_4, or CR_4R_5; wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

14. The compound of claim 1, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 1;

G is CH_2 or –(C=O); and

X is O, S, C=O, S=O, C=CR_4R_5, NR_4, or CR_4R_5; wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

15. The compound of claim 1, wherein the compound has the structure:



;

wherein R_1 and R_2 are as defined in claim 1;

G is CH_2 or –(C=O); and

X is O, S, C=O, S=O, C=CR_4R_5, NR_4, or CR_4R_5; wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

16. The compound of claim 1, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 1;

p is an integer from 0-3;

s is an integer from 0-4;

A, B, D, E and each occurrence of K are independently absent, O, S, -C=O, -S=O, $-C=CR_4R_5$, $-NR_4$, or $-CR_4R_5$, wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano, $-OR_x$, $-SR_x$, $-NR_xR_y$, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; and wherein A and B, B and D, D and E, E and K and any two adjacent K groups may be linked by a single or double bond as valency permits; wherein each occurrence of R_x and R_y is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl, heteroaryl aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moieties may be independently substituted or unsubstituted.

17. The compound of any one of claims 1-16, wherein R_1 is NH_2.

18. The compound of any one of claims 1-16, wherein R_1 is hydrogen.

19. The compound of any one of claims 1-16, wherein R_2 is NH_2, OH, C_1-C_6 alkyl or C_1-C_6 alkenyl, said alkyl and alkenyl groups optionally substituted with halogen or hydroxyl.

20. The compound of any one of claims 1-16, wherein R_2 is C_1-C_2 alkyl.

21. The compound of any one of claims 1-16, wherein R_2 is methyl.

22. The compound of any one of claims 1-16, wherein R_2 is hydrogen.

23. The compound of any one of claims 4-10, wherein one of R_F or R_G is hydrogen or lower alkyl; and the other is an alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.

24. The compound of any one of claims 4-10, wherein one of R_F or R_G is hydrogen or lower alkyl; and the other is an aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.

25. The compound of claim 24, wherein one of R_F or R_G is hydrogen or lower alkyl; and the other is phenyl, pyridyl, (alkyl)phenyl, or (alkyl)pyridyl, optionally substituted with one or more occurrences of halogen, trifluromethoxy, methoxy, trifluoromethyl, methylthio, or substituted or unsubstituted lower alkyl, lower heteroalkyl, aryl or heteroaryl.

26. The compound of any one of claims 4-10, wherein one of R_F or R_G is hydrogen or lower alkyl; and the other is a cyclic or acyclic, linear or branched, saturated or unsaturated aliphatic moiety optionally substituted with one or more of substituted or unsubstituted aryl, heteroaryl, amide, alkoxy, hydroxyl, thioalkyl, thiol, acyl or amino.

27. The compound of claim 11, wherein R_F is an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally

independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.

28. The compound of claim 12, wherein R_F is hydrogen, a protecting group, or an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.

29. A pharmaceutical composition comprising a compound having the structure (I):



(I)

and pharmaceutically acceptable derivatives thereof;

wherein n is an integer from 0-4;

R_1 is hydrogen, $-NH_2$, -NHMe, -NHAc, -OH, F, -OMe, -CN, or -NH(C=O)OEt;

R_2 is hydrogen, $-NR_AR_B$, $-OR_A$, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_A and R_B are each independently hydrogen or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

each occurrence of R_3 is independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group $-G-R_C$, wherein G is absent or is $-CH_2-$, $-NR_D-$, -O-, or (C=O), and wherein R_C is hydrogen, $-NR_FR_G$, $-OR_F$, $-SR_F$, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_D, R_F and R_G are each independently hydrogen, $-NR_xR_y$, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_D and R_C or R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R_x and R_y is independently hydrogen, an aliphatic, cycloaliphatic,

heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_x and R_y taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted; and

a pharmaceutically acceptable carrier or diluent; and optionally further comprising an additional therapeutic agent.

30. The pharmaceutical composition of claim 29, wherein the compound is present in an amout effective to inhibit inflammatory cytokine pathway.

31. The pharmaceutical composition of claim 29, wherein the compound is present in an amout effective to inhibit cell proliferation.

32. The pharmaceutical composition of claim 29, wherein the compound is present in an amout effective to exhibit an anti-inflammatory effect.

33. The pharmaceutical composition of claim 29, wherein the compound has the structure:



;

wherein R_{3a} and R_{3b} are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group –G-R_C, wherein G is absent, $-CH_2-$,

$-NR_D-$, -O-, or (C=O), and wherein R_C is hydrogen, $-NR_FR_G$, $-OR_F$, $-SR_F$, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_D, R_F and R_G are each independently hydrogen, $-NR_xR_y$, an aliphatic, cycloaliphatic, heteroaliphatic,

cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_D and R_C or R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R_x and R_y is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_x and R_y taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

34. The pharmaceutical composition of claim 29, wherein the compound has the structure:



;

wherein R_{3a} and R_{3b} are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group $-G-R_C$, wherein G is absent, $-CH_2-$,

$-NR_D-$, -O-, or (C=O), and wherein R_C is hydrogen, $-NR_FR_G$, $-OR_F$, $-SR_F$, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_D, R_F and R_G are each independently hydrogen, $-NR_xR_y$, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_D and R_C or R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R_x and R_y is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an

aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_x and R_y taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

35. The pharmaceutical composition of claim 29, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 29.

36. The pharmaceutical composition of claim 29, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 29.

37. The pharmaceutical composition of claim 29, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 29.

38. The pharmaceutical composition of claim 29, wherein the compound has the structure:



wherein q and r are each independently 0 or 1; and R_1, R_2, R_F and R_G are as defined in claim 29.

39. The pharmaceutical composition of claim 29, wherein the compound has the structure:



wherein q and r are each independently 0 or 1; and R_1, R_2, R_F and R_G are as defined in claim 29.

40. The pharmaceutical composition of claim 29, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 29.

41. The pharmaceutical composition of claim 29, wherein the compound has the structure:



;

wherein R_1, R_2, R_F and R_G are as defined in claim 29.

42. The pharmaceutical composition of claim 29, wherein the compound has the structure:



;

wherein R_1 and R_2 are as defined in claim 29;

m is 0, 1 or 2; and

R_F is an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

43. The pharmaceutical composition of claim 29, wherein the compound has the structure:



;

wherein R_1 and R_2 are as defined in claim 29; and

R_F is hydrogen, a protective group or an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

44. The pharmaceutical composition of claim 29, wherein the compound has the structure:



;

wherein R_1 and R_2 are as defined in claim 29;

G is CH_2 or –(C=O); and

X is O, S, C=O, S=O, $C=CR_4R_5$, NR_4, or CR_4R_5; wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

45. The pharmaceutical composition of claim 29, wherein the compound has the structure:



;

wherein R_1 and R_2 are as defined in claim 29;

G is CH_2 or –(C=O); and

X is O, S, C=O, S=O, $C=CR_4R_5$, NR_4, or CR_4R_5; wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

46. The pharmaceutical composition of claim 29, wherein the compound has the structure:



;

wherein R_1 and R_2 are as defined in claim 29;

G is CH_2 or –(C=O); and

X is O, S, C=O, S=O, $C=CR_4R_5$, NR_4, or CR_4R_5; wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

47. The pharmaceutical composition of claim 29, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 29;

p is an integer from 0-3;

s is an integer from 0-4;

A, B, D, E and each occurrence of K are independently absent, O, S, -C=O, -S=O, $-C=CR_4R_5$, $-NR_4$, or $-CR_4R_5$, wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano, $-OR_x$, $-SR_x$, $-NR_xR_y$, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; and wherein A and B, B and D, D and E, E and K and any two adjacent K groups may be linked by a single or double bond as valency permits; wherein each occurrence of R_x and R_y is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl, heteroaryl aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moieties may be independently substituted or unsubstituted.

48. The pharmaceutical composition of any one of claims 29-47, wherein R_1 is NH_2.

49. The pharmaceutical composition of any one of claims 29-47, wherein R_1 is hydrogen.

50. The pharmaceutical composition of any one of claims 29-47, wherein R_2 is NH_2, OH, C_1-C_6 alkyl or C_1-C_6 alkenyl, said alkyl and alkenyl groups optionally substituted with halogen or hydroxyl.

51. The pharmaceutical composition of any one of claims 29-47, wherein R_2 is C_1-C_2 alkyl.

52. The pharmaceutical composition of any one of claims 29-47, wherein R_2 is methyl.

53. The pharmaceutical composition of any one of claims 29-47, wherein R_2 is hydrogen.

54. The pharmaceutical composition of any one of claims 35-41, wherein one of R_F or R_G is hydrogen or lower alkyl; and the other is an alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.

55. The pharmaceutical composition of any one of claims 35-41, wherein one of R_F or R_G is hydrogen or lower alkyl; and the other is an aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.

56. The pharmaceutical composition of claim 55, wherein one of R_F or R_G is hydrogen or lower alkyl; and the other is phenyl, pyridyl, (alkyl)phenyl, or (alkyl)pyridyl, optionally substituted with one or more occurrences of halogen, trifluromethoxy, methoxy, trifluoromethyl, methylthio, or substituted or unsubstituted lower alkyl, lower heteroalkyl, aryl or heteroaryl.

57. The pharmaceutical composition of any one of claims 35-41, wherein one of R_F or R_G is hydrogen or lower alkyl; and the other is a cyclic or acyclic, linear or branched, saturated or unsaturated aliphatic moiety optionally substituted with one or

more of substituted or unsubstituted aryl, heteroaryl, amide, alkoxy, hydroxyl, thioalkyl, thiol, acyl or amino.

58. The pharmaceutical composition of claim 42, wherein R_F is an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.

59. The pharmaceutical composition of claim 43, wherein R_F is hydrogen, a protecting group, or an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.

60. A method for treating an inflammatory or autoimmune disorder or proliferative disorder comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound having the structure (I):



(I)

and pharmaceutically acceptable derivatives thereof;

wherein n is an integer from 0-4;

R_1 is hydrogen, $-NH_2$, -NHMe, -NHAc, -OH, F, -OMe, -CN, or -NH(C=O)OEt;

R_2 is hydrogen, $-NR_AR_B$, $-OR_A$, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_A and R_B are each independently hydrogen or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

each occurrence of R_3 is independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group $-G-R_C$, wherein G is

absent or is $-CH_2-$, $-NR_D-$, -O-, or (C=O), and wherein R_C is hydrogen, $-NR_FR_G$, $-OR_F$, $-SR_F$, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_D, R_F and R_G are each independently hydrogen, $-NR_xR_y$, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_D and R_C or R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R_x and R_y is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_x and R_y taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted; and

a pharmaceutically acceptable carrier or diluent; and optionally further comprising administering an additional therapeutic agent.

61. The method of claim 60, wherein the compound has the structure:



;

wherein R_{3a} and R_{3b} are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group $-G-R_C$, wherein G is absent, $-CH_2-$,

$-NR_D-$, -O-, or (C=O), and wherein R_C is hydrogen, $-NR_FR_G$, $-OR_F$, $-SR_F$, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_D, R_F and R_G are each independently hydrogen, $-NR_xR_y$, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_D and R_C or R_F and

R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R_x and R_y is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_x and R_y taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

62. The method of claim 60, wherein the compound has the structure:



;

wherein R_{3a} and R_{3b} are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group –G-R_C, wherein G is absent, $–CH_2-$,

$-NR_D-$, -O-, or (C=O), and wherein R_C is hydrogen, $–NR_FR_G$, $-OR_F$, $-SR_F$, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R_D, R_F and R_G are each independently hydrogen, $-NR_xR_y$, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_D and R_C or R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R_x and R_y is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R_x and R_y taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

63. The method of claim 60, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 60.

64. The method of claim 60, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 60.

65. The method of claim 60, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 60.

66. The method of claim 60, wherein the compound has the structure:



wherein q and r are each independently 0 or 1; and R_1, R_2, R_F and R_G are as defined in claim 60.

67. The method of claim 60, wherein the compound has the structure:



wherein q and r are each independently 0 or 1; and R_1, R_2, R_F and R_G are as defined in claim 60.

68. The method of claim 60, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 60.

69. The method of claim 60, wherein the compound has the structure:



wherein R_1, R_2, R_F and R_G are as defined in claim 60.

70. The method of claim 60, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 60;

m is 0, 1 or 2; and

R_F is an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

71. The method of claim 60, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 60; and

R_F is hydrogen, a protective group or an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

72. The method of claim 60, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 60;

G is CH_2 or –(C=O); and

X is O, S, C=O, S=O, $C=CR_4R_5$, NR_4, or CR_4R_5; wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

73. The method of claim 60, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 60;

G is CH_2 or –(C=O); and

X is O, S, C=O, S=O, $C=CR_4R_5$, NR_4, or CR_4R_5; wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

74. The method of claim 60, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 60;

G is CH_2 or –(C=O); and

X is O, S, C=O, S=O, $C=CR_4R_5$, NR_4, or CR_4R_5; wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

75. The method of claim 60, wherein the compound has the structure:



wherein R_1 and R_2 are as defined in claim 60;

p is an integer from 0-3;

s is an integer from 0-4;

A, B, D, E and each occurrence of K are independently absent, O, S, -C=O, -S=O, $-C=CR_4R_5$, $-NR_4$, or $-CR_4R_5$, wherein each occurrence of R_4 and R_5 is independently hydrogen, hydroxyl, halogen, cyano, $-OR_x$, $-SR_x$, $-NR_xR_y$, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; and wherein A and B, B and D, D

and E, E and K and any two adjacent K groups may be linked by a single or double bond as valency permits; wherein each occurrence of R_x and R_y is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl, heteroaryl aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moieties may be independently substituted or unsubstituted.

76. The method of any one of claims 60-75, wherein in the compound R_1 is NH_2.

77. The method of any one of claims 60-75, wherein in the compound R_1 is hydrogen.

78. The method of any one of claims 60-75, wherein in the compound R_2 is NH_2, OH, C_1-C_6 alkyl or C_1-C_6 alkenyl, said alkyl and alkenyl groups optionally substituted with halogen or hydroxyl.

79. The method of any one of claims 60-75, wherein in the compound R_2 is C_1-C_2 alkyl.

80. The method of any one of claims 60-75, wherein in the compound R_2 is methyl.

81. The method of any one of claims 60-75, wherein in the compound R_2 is hydrogen.

82. The method of any one of claims 63-69, wherein in the compound one of R_F or R_G is hydrogen or lower alkyl; and the other is an alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein R_F and R_G taken

together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.

83. The method of any one of claims 63-69, wherein in the compound one of R_F or R_G is hydrogen or lower alkyl; and the other is an aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein R_F and R_G taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.

84. The method of claim 83, wherein in the compound one of R_F or R_G is hydrogen or lower alkyl; and the other is phenyl, pyridyl, (alkyl)phenyl, or (alkyl)pyridyl, optionally substituted with one or more occurrences of halogen, trifluromethoxy, methoxy, trifluoromethyl, methylthio, or substituted or unsubstituted lower alkyl, lower heteroalkyl, aryl or heteroaryl.

85. The method of any one of claims 63-69, wherein in the compound one of R_F or R_G is hydrogen or lower alkyl; and the other is a cyclic or acyclic, linear or branched, saturated or unsaturated aliphatic moiety optionally substituted with one or more of substituted or unsubstituted aryl, heteroaryl, amide, alkoxy, hydroxyl, thioalkyl, thiol, acyl or amino.

86. The method of claim 70, wherein in the compound R_F is an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.

87. The method of claim 71, wherein in the compound R_F is hydrogen, a protecting group, or an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.

88. The method of claim 60, wherein the inflammatory or autoimmune disorder or proliferative disorder is rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases (CNS) such as multiple sclerosis, systemic lupus erythematosus, asthma, allograft rejection/graft versus host disease (GVHD), psoriasis, atopic dermatitis, eczema, uticaria, allergic rhinitis, myasthenia gravis, diabetes, idiopathic thrombocytopenia purpura, glomerulonephritis, cardiovascular disease, or cancer.

89. The method of claim 60, wherein the inflammatory disorder is rheumatoid arthritis.

90. The method of claim 60, wherein the inflammatory disorder is ulcerative colitis/Crohn's disease.

91. The method of claim 60, wherein the inflammatory disorder is multiple sclerosis.

92. The method of claim 60, wherein the inflammatory disorder is asthma.

93. The method of claim 60, wherein the inflammatory disorder is psoriasis.

94. The method of claim 60, wherein the inflammatory disorder is allograft rejection/GVHD.

95. The method of claim 60, wherein the inflammatory disorder is idiopathic thrombocytopenia purpura.

96. The method of claim 60, wherein the inflammatory disorder is allergic rhinitis.

97. The method of claim 60, wherein the inflammatory disorder is atopic dermatitis.

98. The method of claim 60, wherein the inflammatory disorder is systemic lupus erythematosus.

99. The method of claim 60, wherein the inflammatory disorder is glomerulonephritis.

100. The method of claim 60, wherein the inflammatory disorder is diabetes.